Search

B Discussion: b MRD analysis and PET scan are independent and complementary prognostic tools in FL: a MRD positivity in the two years after immuno-chemotherapy is predictive of POD24 and dismal PFS independently from the EoI PET result. This means that patients scoring PET- at EoI but showing a persistent or reappearing MRD+ signal during the following 24 months had a dismal PFS, superimposable to that of PET+ patients (Figure 1C). B Introduction: b In follicular lymphoma (FL), FDG-PET is routinely employed to evaluate response at the end of induction (EoI), while minimal residual disease (MRD) analysis is highly reliable in predicting relapse over the entire disease history. [Extracted from the article]

In the whole population of 690 patients, the tMTV threshold to categorized low and high tumor burden was 224 and 194 ml with and without sMTV, respectively. During the segmentation procedure, it has been observed that frequently spleen MTV (sMTV) heavily influenced the tMTV value, particularly in case of diffuse spleen uptake included in tMTV calculation. [Extracted from the article]

We employed a deep gene expression analysis searching for molecular determinants that could anticipate the risk of relapse among patients who achieve a complete metabolic response after 2 ABVD courses (iPET-). Kaplan Meyer curve analysis showed that Cluster 2 patients had a significative reduced PFS as compared to Cluster 1 ( I p i = 0.00043), supporting the prognostic relevance of these genes (Figure 1B). [Extracted from the article]

Analizar las características epidemiológicas y antropométricas de los pacientes con activación de la grasa parda detectada por tomografía por emisión de positrones con fluoruro 18-fluorodeoxiglucosa/tomografía computarizada (18F-FDG PET/TC). De 2005 a 2017, se incluyeron retrospectivamente 818 estudios PET/TC con 18F-FDG positivos para detección de grasa parda, 742 exámenes realizados en población adulta y 76 PET/TC en población pediátrica. Se realizó una prueba de Chi cuadrado para comparar la distribución de las características entre pacientes adultos y pediátricos. Los adultos mostraron una tasa más alta de detección de grasa parda en mujeres (79% vs. 61%, p < 0,001) y en pacientes con hiperglucemia (> 100 mg/dl) (24% vs. 16%, p = 0,02), no se encontraron diferencias significativas considerando el sobrepeso (IMC > 25 kg/m2) (22% vs. 20%, p = 0,55). Teniendo en cuenta solo a mujeres, los adultos mostraron una tasa más alta de detección de grasa parda tanto en pacientes con hiperglucemia (83% frente a 42%, p < 0,001), como en pacientes con sobrepeso (80% frente a 67%, p = 0,005). En ambas poblaciones, la activación de la grasa parda ocurrió con mayor frecuencia en las estaciones frías; no hubo diferencias significativas en la distribución considerando la temporada de nacimiento (p = 0,2). El sexo, la glucemia y el IMC desempeñan un papel importante en la predicción de la activación de la grasa parda, con diferencias significativas entre adultos y niños. Se confirma que la exposición al frío es un factor de predicción importante, mientras que la temporada de nacimiento no es significativa. To analyze epidemiological and anthropometric features of patients with brown adipose tissue (BAT) activation detected by fluorine18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). From 2005 to 2017, 818 18F-FDG PET/CT studies positive for BAT detection were retrospectively included, 742 examinations performed on the adult population and 76 PET/CT on the pediatric population. A Chi-squared test was performed to compare features distribution between the adult and pediatric patients. Adults showed a higher rate of BAT detection in females (79% vs. 61%, P <0.001) and in hyperglycaemic patients (>100 mg/dL) (24% vs. 16%, P =0.02), no significant difference was found with regard to overweight patients (BMI > 25 kg/m2) (22% vs. 20%, P =.55). Considering females only, the adults showed a higher rate of BAT detection both in hyperglycaemic (83% vs. 42%, P <0.001) and overweight patients (80% vs. 67%, P =0.005). In both populations BAT activation happened more frequently in cold seasons; there was no significant distribution difference with regard to season of birth (P= 0.2). Sex, glycemia and BMI play a major role in predicting BAT activation, with significant differences between adults and pediatric patients. Cold exposure is confirmed as an important predicting factor, while season of birth is not significant. [ABSTRACT FROM AUTHOR]

B Aim: b To assess the prognostic value of the PET metabolic response using the Deauville Score at the end of induction (EoI) therapy. In the whole population, the 5 yrs PFS (95% CI) in DS1-2, DS 3 ad DS4-5 was 74% (69-78), 55% (44-65; HR1.90 (1.36-2.66) I p i < 0.001) and 37%(26-48; HR 4.01 (2.90-5.54) I p i < 0.001); DS3 patients had an intermediate 5 yrs PFS rates between those of DS1-2 and DS4-5 patients. B Conclusion: b In FOLL12 trial, EoI-PET according DS criteria was a reliable tool to stratify PFS and OS in advanced follicular lymphoma patients treated with immunochemotherapy; in addition, these data showed DS3 patients as a new category with an intermediate prognosis in terms of PFS. [Extracted from the article]